These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 7952800)

  • 1. Steady-state plasma concentrations of propafenone--chirality and metabolism.
    Volz M; Mitrovic V; Schlepper M
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):370-5. PubMed ID: 7952800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state plasma kinetics of slow-release propafenone, its two isomers and its main metabolites.
    Volz M; Mitrovic V; Thiemer J; Schlepper M
    Arzneimittelforschung; 1995 Mar; 45(3):246-9. PubMed ID: 7741777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of the degree of oxidative hepatic metabolism in conditioning the pharmacokinetics and the pharmacodynamics of propafenone].
    Boriani G; Capucci A; Strocchi E; Marchesini B; Baroni M; Frabetti L; Ambrosioni E; Magnani B
    G Ital Cardiol; 1991 May; 21(5):517-26. PubMed ID: 1936756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.
    Botsch S; Gautier JC; Beaune P; Eichelbaum M; Kroemer HK
    Mol Pharmacol; 1993 Jan; 43(1):120-6. PubMed ID: 8423765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
    Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study].
    Lardoux H; Maison Blanche P; Marchand X; Canler A; Rouesnel P; Bleinc D; Péraudeau P; Scheck F
    Ann Cardiol Angeiol (Paris); 1996 Oct; 45(8):469-79. PubMed ID: 8952741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.
    Funck-Brentano C; Kroemer HK; Pavlou H; Woosley RL; Roden DM
    Br J Clin Pharmacol; 1989 Apr; 27(4):435-44. PubMed ID: 2719900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Double-blind randomized placebo-controlled study of the effects of slow release and immediate release forms of propafenone in patients ventricular extrasystole symptoms].
    Mastropasqua F; Totaro P; Massari F; Pitzalis MV; Rizzon P
    Cardiologia; 1998 Jun; 43(6):617-23. PubMed ID: 9675961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Propafenone and flecainide in the therapy of ventricular arrhythmias].
    Paperini L; Davini A; Lattanzi F; Topi A; Reisenhofer B; Squarcini G; Paci A; Topi PL
    Minerva Cardioangiol; 1995 Oct; 43(10):449-57. PubMed ID: 8819814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.
    Siddoway LA; Thompson KA; McAllister CB; Wang T; Wilkinson GR; Roden DM; Woosley RL
    Circulation; 1987 Apr; 75(4):785-91. PubMed ID: 3829342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone.
    Lee JT; Kroemer HK; Silberstein DJ; Funck-Brentano C; Lineberry MD; Wood AJ; Roden DM; Woosley RL
    N Engl J Med; 1990 Jun; 322(25):1764-8. PubMed ID: 1971708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia.
    Cai WM; Xu J; Chen B; Zhang FM; Huang YZ; Zhang YD
    Acta Pharmacol Sin; 2002 Nov; 23(11):1040-4. PubMed ID: 12421483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of propafenone metaboliser phenotype from plasma and urine excretion data.
    Latini R; Belloni M; Bernasconi R; Cappiello E; Giani P; Landolina M; Leopaldi D; Castel JM
    Eur J Clin Pharmacol; 1992; 42(1):111-4. PubMed ID: 1541308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology and beta-blocking efficacy of propafenone.
    Barbey JT
    J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S41-3. PubMed ID: 1723117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacogenetic study of the response to flecainide and propafenone in patients with atrial fibrillation].
    Martínez-Sellés M; Castillo I; Montenegro P; Martín ML; Almendral J; Sanjurjo M
    Rev Esp Cardiol; 2005 Jun; 58(6):745-8. PubMed ID: 15970126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of the anti-arrhythmic action of propafenone treatment and its influence on left ventricular function].
    Saitta A; Bonaiuto M; Mileto A; Oriti S; Cinquegrani M; Giordano G; Fodale P; Saitta M; Squadrito F
    Clin Ter; 1993 Apr; 142(4):351-60. PubMed ID: 8330479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial.
    Mörike K; Kivistö KT; Schaeffeler E; Jägle C; Igel S; Drescher S; Fux R; Marx C; Hofmann U; Engel C; Wagner F; Delabar U; Meisner C; Bail D; Böhm JO; Gleiter CH; Ziemer G; Rein JG; Hellberg KD; Eichelbaum M; Schwab M
    Clin Pharmacol Ther; 2008 Jul; 84(1):104-10. PubMed ID: 18167502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Propafenone Research Group.
    Zoble RG; Kirsten EB; Brewington J
    Clin Pharmacol Ther; 1989 May; 45(5):535-41. PubMed ID: 2721109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Low-dose propafenone in chronic ventricular arrhythmia: evaluation by linear regression analysis and correlation with the plasma concentrations of the drug].
    Vitale P; De Stefano R; Perna B; Romano A; Iacono A
    Cardiologia; 1986 Apr; 31(4):303-10. PubMed ID: 3791323
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasma propafenone concentration in the evaluation of anti-arrhythmic efficacy.
    Steurer G; Weber H; Schmidinger H; Plass H; Frey B; Pürerfellner H; Probst P
    Eur Heart J; 1991 Apr; 12(4):526-32. PubMed ID: 2065687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.